Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
Peptides 125:170225 (2020)
The continued global growth in the prevalence of obesity coupled with the limited number of efficacious and safe treatment options elevates the importance of innovative pharmaceutical approaches. Combinatorial strategies that harness the metabolic benefits of multiple hormonal mechanisms have emerged at the preclinical and more recently clinical stages of drug development. A priority has been anti-obesity unimolecular peptides that function as balanced, high potency poly-agonists at two or all the cellular receptors for the endocrine hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This report reviews recent progress in this area, with emphasis on what the initial clinical results demonstrate and what remains to be addressed.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Obesity ; Type 2 Diabetes ; Poly-agonism ; Gip ; Glp-1 ; Glucagon; Dependent Insulinotropic Polypeptide; High-fat Diet; Peptide-1 Receptor; Body-weight; Bariatric Surgery; Corrects Obesity; Glycemic Control; Clinical-trials; Hybrid Peptide; Co-agonism
ISSN (print) / ISBN
0196-9781
e-ISSN
1873-5169
Journal
Peptides
Quellenangaben
Volume: 125,
Article Number: 170225
Publisher
Elsevier
Publishing Place
New York, NY
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)